Do you want to read an article? Please log in or register.
CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non-Small Cell Lung Cancer
Lung, Respiratory and Thoracic Cancer
Related content
Lung, Respiratory and Thoracic Cancer
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17
Eur J Cancer
Mark M, Froesch P, Gysel K, Rothschild SI, Addeo A, Ackermann CJ, Chiquet S, Schneider M, Ribi K, Maranta AF, Bastian S, von Moos R, Joerger M, Früh M, Swiss Group for Clinical Cancer Research (SAKK)
doi: 10.1016/j.ejca.2024.113600
Lung, Respiratory and Thoracic Cancer
Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer
Lung Cancer
Bauman JR, Liu G, Preeshagul I, Liu SV, Melosky B, Abrahami D, Li B, Thomaidou D, Duncan K, Krulewicz S, Rupp M, Lin JJ
doi: 10.1016/j.lungcan.2024.107919
Lung, Respiratory and Thoracic Cancer
Real-world comparative effectiveness of sotorasib versus docetaxel in second line and beyond among patients with advanced non-small cell lung cancer (NSCLC)
Lung Cancer
Johnson M, Younan D, Kent ST, Mesa-Frias M, Alan Brookhart M, Balasubramanian A, Spira A
doi: 10.1016/j.lungcan.2024.107960
Lung, Respiratory and Thoracic Cancer
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
Ann Oncol
Felip E, Cho BC, Gutiérrez V, Alip A, Besse B, Lu S, Spira AI, Girard N, Califano R, Gadgeel SM, Yang JC, Yamamoto S, Azuma K, Kim YJ, Lee KH, Danchaivijitr P, Ferreira CG, Cheng Y, Sendur MAN, Chang GC, Wang CC, Prabhash K, Shinno Y, Stroyakovskiy D, Paz-Ares L, Rodriguez-Cid JR, Martin C, Campelo MRG, Hayashi H, Nguyen D, Tomasini P, Gottfried M, Dooms C, Passaro A, Schuler M, Gelatti ACZ, Owen S, Perdrizet K, Ou SI, Curtin JC, Zhang J, Gormley M, Sun T, Panchal A, Ennis M, Fennema E, Daksh M, Sethi S, Bauml JM, Lee SH
doi: 10.1016/j.annonc.2024.05.541
Lung, Respiratory and Thoracic Cancer
Accelerated hypofractionated radiotherapy for locally-advanced non-small cell lung cancer: A systematic review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee
J Thorac Oncol
Said BI, Geng Y, Badiyan SN, Bang A, Bezjak A, Chua KLM, Faivre-Finn C, Kong FM, Przybysz D, Putora PM, Munoz-Schuffenegger P, Siva S, Xu-Welliver M, McDonald F, Louie A, Chun SG
doi: 10.1016/j.jtho.2024.09.1437
Lung, Respiratory and Thoracic Cancer
Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence
Lung Cancer
Nadal E, Rifi N, Kane S, Mbacke S, Starkman L, Suero B, Le H, Samjoo IA
doi: 10.1016/j.lungcan.2024.107816
Lung, Respiratory and Thoracic Cancer
Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC)
Lung Cancer
Ou SH, Kilvert H, Candlish J, Lee B, Polli A, Thomaidou D, Le H
doi: 10.1016/j.lungcan.2024.107968
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial
★ 1
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Nat Med
Peters S, Gadgeel SM, Mok T, Nadal E, Kilickap S, Swalduz A, Cadranel J, Sugawara S, Chiu CH, Yu CJ, Moskovitz M, Tanaka T, Nersesian R, Shagan SM, Maclennan M, Mathisen M, Bhagawati-Prasad V, Diarra C, Assaf ZJ, Archer V, Dziadziuszko R
doi: 10.1038/s41591-024-03008-4
Lung, Respiratory and Thoracic Cancer
Iruplinalkib (WX-0593) versus crizotinib in ALK TKI-naïve locally advanced or metastatic ALK-positive non-small cell lung cancer: interim analysis of a randomized, open-label, phase III study (INSPIRE)
J Thorac Oncol
Shi Y, Chen J, Yang R, Wu H, Wang Z, Yang W, Cui J, Zhang Y, Liu C, Cheng Y, Liu Y, Shan J, Wang D, Yang L, Hu C, Zhao J, Cao R, Tan B, Xu K, Si M, Li H, Mao R, Li L, Kang X, Wang L
doi: 10.1016/j.jtho.2024.01.013